Tema Heart & Health ETF (NASDAQ:HRTS) Shares Shorted: Short Interest Down 43.3% in September

Tema Heart & Health ETF (NASDAQ:HRTS) was the target of a large drop in short interest in the month of September. As of September 30th, there was short interest totaling 520 shares, a drop of 43.3% from the September 15th total of 917 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 1,835 shares, the days-to-cover ratio is currently 0.3 days.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. XML Financial LLC purchased a new stake in Tema Heart & Health ETF during the 2nd quarter worth $223,000. Anson Capital Inc. purchased a new position in Tema Heart & Health ETF in the 2nd quarter valued at about $297,000. Members Advisory Group LLC purchased a new position in Tema Heart & Health ETF in the 2nd quarter valued at about $398,000. Royal Bank of Canada grew its stake in shares of Tema Heart & Health ETF by 8.8% during the first quarter. Royal Bank of Canada now owns 21,083 shares of the company’s stock valued at $710,000 after acquiring an additional 1,703 shares in the last quarter. Finally, Rothschild Capital Partners LLC acquired a new stake in shares of Tema Heart & Health ETF during the second quarter valued at about $651,000.

Tema Heart & Health ETF Price Performance

Tema Heart & Health ETF stock traded up $0.94 during midday trading on Thursday, hitting $37.28. 950 shares of the company were exchanged, compared to its average volume of 5,316. The company’s fifty day moving average price is $36.95 and its 200-day moving average price is $35.54. The company has a market cap of $55.17 million, a PE ratio of 22.06 and a beta of 0.65. Tema Heart & Health ETF has a fifty-two week low of $31.95 and a fifty-two week high of $38.87.

About Tema Heart & Health ETF

The Tema Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive. HRTS was launched on Nov 20, 2023 and is issued by Tema.